martes, 28 de agosto de 2018

China's first cancer immunotherapy will cost half of what it costs in the U.S.

China's first cancer immunotherapy will cost half of what it costs in the U.S.

Cancer Briefing

STAT Plus: China’s first cancer immunotherapy will be priced at about half of what it costs in the U.S.

By REBECCA ROBBINS


MEL EVANS/AP
The blockbuster cancer drug Opdivo, made by Bristol-Myers Squibb, will be sold for about $84,000 per year in the Chinese market, before discounts.

No hay comentarios: